Data were retrieved from 176 between September 2011 and October 2016.
With a mean age of 67.02 years and a PSA at diagnosis of 7.1 ng/mL. The
majority Gleason grade was 6 (3+3) in 154 patients (87.5%) with the affected
lobe being left in 45%, right 32% and bilateral in 23%. The mean pre-implant
measured prostate volume was 37.98 cc and at the time of implantation 34.47 cc
with a mean volume difference of 2.6 cc. A mean of 65.65 seeds were used with
19.77 in each treatment.
The mean total activity was 34.23 mCi with a mean V100% of 97.51, D90
176.24 Gy, D2cc straight 86.67 Gy and D30 urethra mean 172.12 Gy.
Urinary toxicity at one month after completion was 48% (G3 4%) and
rectal 5% (G3 0%). At 1 year urinary toxicity was 24% (G3 3%) and rectal
toxicity 7% (G3 20%). At 5 years, urinary toxicity was 11% (G3 0%) and rectal
toxicity was 2% (G3 0%).
With a follow-up of 60.19 months 10 patients presented biochemical
recurrences (5.68%) and 10 patients died (5.68%) with independent prostate
cancer.
The mean pre-treatment baseline IPSS was 6.96 points, increasing to
16.23 at 3 months after implantation and progressively decreasing to 7.14
points at 5.5 years of follow-up, which shows a mean decrease of 0.18 points.
Similarly, the mean initial quality of life was 1.54 points, reaching
3.18 at 3 months after treatment and decreasing to 1.42 at 5.5 years of
follow-up (mean decrease of 0.12 points).
The mean initial IIEF-6 was 13.13 points decreasing to 8.26 at 3 months
and increasing again to 11.45 at 5.5 years follow-up (mean decrease of 1.68
points).
Mean PSA at 5.5 years decreased to 0.16 ng/mL.